Case Background
The client is a multinational enterprise specializing in orthopedic implant medical devices, with its headquarters in Australia. Its business covers the EU, Southeast Asia, and the Chinese market, boasting 2 core product lines and 3 overseas subsidiaries. With the updates to global medical device regulations (EU MDR, Australian TGA) and intensifying market competition, the enterprise faced three core pain points: first, the high tax burden of its European subsidiaries (28% comprehensive tax rate) and rising R&D and compliance costs; second, the lack of a clear strategy for expanding into the Asia-Pacific market, inefficient existing distribution channels, and slowing revenue growth; third, non-compliant cross-border capital flows and related-party transaction pricing, posing risks of tax audits.
1. Tax Compliance and Optimization Planning
Targeting the characteristics of the enterprise’s cross-border operations, we established a dual system of “regional tax burden balance + compliance risk prevention and control”: first, restructuring the overseas structure by assisting in setting up a regional operation center in Ireland. Leveraging Ireland’s 12.5% corporate income tax rate and tax incentives for medical device IP income, we integrated R&D and sales functions in the European region, reasonably divided related-party transaction pricing, and legally enjoyed tax treaty preferences; second, optimizing R&D expense deductions by sorting out R&D investments in both Australia and the EU, accurately collecting deductible items, and applying for Australian R&D Tax Incentive and EU R&D expense additional deductions to reduce comprehensive R&D costs; third, standardizing cross-border capital flows by designing a compliant capital pool model to solve the efficiency problem of capital allocation between the Asia-Pacific and European regions and avoid transfer pricing investigation risks.
2. Market Expansion and Operational Optimization Consulting
Combining medical industry regulations and market demands, we provided full-process expansion strategy support: first, formulating Asia-Pacific market layout planning. In response to the growing medical demand in Southeast Asia, we selected Indonesia and Thailand as core markets, designed a phased expansion path of “local distribution + cooperative manufacturing”, assisted in connecting with local medical regulatory authorities to complete product registration and filing, and shortened the market access cycle; second, optimizing distribution channels by evaluating the effectiveness of 12 existing Asia-Pacific distributors, eliminating inefficient partners, establishing a two-level channel system of “core dealers + regional service providers”, and formulating standardized cooperation agreements and rebate mechanisms; third, reconstructing operational processes by connecting the enterprise’s ERP system with the compliance management system, optimizing inventory turnover and order fulfillment processes, and solving the problems of high cold chain transportation costs and long delivery cycles for medical devices.
Implementation Results
After 6 months of integrated service implementation, the enterprise achieved triple breakthroughs in tax burden, strategy, and operations:
– Tax Optimization: The comprehensive tax rate in the European region decreased from 28% to 15%, with annual tax savings exceeding 8 million euros. The Australian R&D tax refund covered 35% of annual R&D investment, legally releasing funds for new product R&D;
– Market Expansion: Successfully entered the Indonesian and Thai markets, completed local product registration, added 5 core dealers, achieved a 42% year-on-year growth in Asia-Pacific revenue, and improved channel turnover efficiency by 30%;
– Compliance and Efficiency: Established a standardized cross-border related-party transaction and capital flow system, successfully passed EU tax audits and Australian TGA compliance reviews, shortened the order fulfillment cycle from 45 days to 20 days, and reduced operational costs by 18%.